[go: up one dir, main page]

DK1133283T3 - Fremgangsmåde til fremstilling af lægemiddelpartikler - Google Patents

Fremgangsmåde til fremstilling af lægemiddelpartikler

Info

Publication number
DK1133283T3
DK1133283T3 DK99963729T DK99963729T DK1133283T3 DK 1133283 T3 DK1133283 T3 DK 1133283T3 DK 99963729 T DK99963729 T DK 99963729T DK 99963729 T DK99963729 T DK 99963729T DK 1133283 T3 DK1133283 T3 DK 1133283T3
Authority
DK
Denmark
Prior art keywords
drug particles
preparation
susceptible
degradation
substance
Prior art date
Application number
DK99963729T
Other languages
Danish (da)
English (en)
Inventor
Catherine Boissier
Anne Mari Juppo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1133283T3 publication Critical patent/DK1133283T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK99963729T 1998-11-23 1999-11-22 Fremgangsmåde til fremstilling af lægemiddelpartikler DK1133283T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9804003A SE9804003D0 (sv) 1998-11-23 1998-11-23 A method of producing drug particles
PCT/SE1999/002152 WO2000030612A1 (fr) 1998-11-23 1999-11-22 Procede de production de particules medicamenteuses

Publications (1)

Publication Number Publication Date
DK1133283T3 true DK1133283T3 (da) 2005-01-24

Family

ID=20413380

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99963729T DK1133283T3 (da) 1998-11-23 1999-11-22 Fremgangsmåde til fremstilling af lægemiddelpartikler

Country Status (12)

Country Link
US (1) US6596315B1 (fr)
EP (1) EP1133283B1 (fr)
JP (1) JP4612191B2 (fr)
AT (1) ATE278390T1 (fr)
AU (1) AU754385B2 (fr)
CA (1) CA2349711C (fr)
DE (1) DE69920945T2 (fr)
DK (1) DK1133283T3 (fr)
ES (1) ES2228148T3 (fr)
PT (1) PT1133283E (fr)
SE (1) SE9804003D0 (fr)
WO (1) WO2000030612A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
CA2290893C (fr) 1999-11-16 2007-05-01 Bernard Charles Sherman Omeprazole de magnesium
GB0016040D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
AUPR197000A0 (en) * 2000-12-08 2001-01-11 Unisearch Limited Synthesis of small particles
AU2002221320B2 (en) * 2000-12-08 2006-06-15 The University Of Sydney Synthesis of small particles
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
CA2478475A1 (fr) 2002-02-25 2003-09-04 Phasex Corporation Procede de sechage de materiaux a base d'eau
ATE551991T1 (de) 2002-04-15 2012-04-15 Map Pharmaceuticals Inc Formulierung aus feinen teilchen mit verflüssigten oder dichten gasen
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
WO2004020436A1 (fr) * 2002-08-30 2004-03-11 Reddy's Laboratories Limited Hydrates amorphes d'esomeprazole magnesium et leur procede de preparation
US20040242642A1 (en) * 2002-11-18 2004-12-02 Dr. Reddy's Laboratories Limited Crystalline esomeprazole compounds and process for the preparation thereof
WO2004098561A2 (fr) 2003-05-08 2004-11-18 Nektar Therapeutics Uk Ltd Materiaux particulaires
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AU2006272438B2 (en) 2005-07-15 2011-08-04 Map Pharmaceuticals, Inc. Method of particle formation
WO2007138606A2 (fr) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Formulation pharmaceutique comprenant des unités multiples
ES2691033T3 (es) 2007-02-11 2018-11-23 Map Pharmaceuticals Inc. Método de administración terapéutica de DHE para activar el alivio rápido de la migraña a la vez que se reduce al mínimo el perfil de los efectos secundarios
MX350838B (es) 2011-02-11 2017-09-18 Grain Proc Corporation * Composicion de sal.
WO2016174664A1 (fr) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Compositions à désintégration par voie orale
WO2017145146A1 (fr) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprenant des inhibiteurs de la pompe à protons
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3744329A1 (de) 1987-12-28 1989-07-06 Schwarz Pharma Gmbh Verfahren zur herstellung einer mindestens einen wirkstoff und einen traeger umfassenden zubereitung
HU209603B (en) 1988-10-05 1994-09-28 Upjohn Co Process for production of solid powders in finalydivided microcristallin form
WO1994008599A1 (fr) * 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Appariement d'ions de medicaments pour ameliorer l'efficacite et l'administration
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE69530325T2 (de) * 1994-12-22 2004-02-19 Astrazeneca Ab Aerosol-arzneiformulierungen
WO1997014407A1 (fr) 1995-10-17 1997-04-24 Research Triangle Pharmaceuticals Administration de medicaments insolubles
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer

Also Published As

Publication number Publication date
US6596315B1 (en) 2003-07-22
PT1133283E (pt) 2005-01-31
EP1133283A1 (fr) 2001-09-19
AU754385B2 (en) 2002-11-14
ATE278390T1 (de) 2004-10-15
ES2228148T3 (es) 2005-04-01
DE69920945T2 (de) 2005-08-25
CA2349711C (fr) 2008-07-15
AU2010200A (en) 2000-06-13
DE69920945D1 (de) 2004-11-11
EP1133283B1 (fr) 2004-10-06
JP4612191B2 (ja) 2011-01-12
SE9804003D0 (sv) 1998-11-23
JP2002530317A (ja) 2002-09-17
CA2349711A1 (fr) 2000-06-02
WO2000030612A1 (fr) 2000-06-02

Similar Documents

Publication Publication Date Title
DK1133283T3 (da) Fremgangsmåde til fremstilling af lægemiddelpartikler
EE200200183A (et) Meetod polüisobuteenfenooli sisaldavate Mannichi aduktide saamiseks
DK0547165T3 (da) Fremgangsmåde til fremstilling af vandopløselige camptothecinanaloger såvel som forbindelserne 10-hydroxy-11-C(1-6)-alkoxyc
DK1914244T3 (da) Fremgangsmåde til at modulere aktiviteten af funktionelle immunmolekyler.
DK1173431T4 (da) Fremgangsmåde til fremstilling af citalopram
DK1242361T3 (da) Fremgangsmåde til fremstilling af tolterodin og analoger deraf såvel som mellemprodukter fremstillet i fremgangsmåden
EA200001129A2 (ru) Способ получения 4-карбоксиамино-2-замещенного-1,2,3,4-тетрагидрохинолина
IS2223B (is) Aðferð til framleiðslu á 5-sýanóþalíði
IS2261B (is) Aðferð til framleiðslu á 5-sýanóþalíði
IS6487A (is) Aðferð til framleiðslu á Sítalóprami
DK1277724T3 (da) Fremgangsmåde til fremstilling af monofluormethylethere
AU2002246702A1 (en) Method of screening for gpr40 ligands
DK1519944T3 (da) Fremgangsmåder til fremstilling af fibrinogen
DK0975790T3 (da) Ny fremgangsmåde til isolering af polysaccharider
DK1017684T3 (da) Kontrastmiddel til afbildning af infarkter og nekroser
NO994822D0 (no) Immunotolerant protrombinkomplekspreparat
DE69927602D1 (de) Verfahren zur herstellung von vitaminpulvern
DK1325022T3 (da) Fremgangsmåde til fremstilling af 21-hydroxy-6,19-oxidoprogesteron (21OH-6OP)
AR042652A1 (es) Bromhidrato de escitalopram y un metodo para su preparacion
DE59903314D1 (de) Perfluor-n-alkansulfonsäure-derivate
DK1456229T3 (da) Fremgangsmåe til fremstilling af echinocandin-derivater
ATE275149T1 (de) Verfahren zur herstellung von taxanderivaten
DK1206452T3 (da) Fremgangsmåde til fremstilling af benzoperhydro-isoindolforbindelser
DK1037613T3 (da) Fremgangsmåde til fremstilling af farmaceutiske formuleringer, der indeholder en ekstrakt
DK1228056T3 (da) Fremgangsmåde til fremstilling af citalopram